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The serine proteinase hepsin 
is an activator of pro-matrix 
metalloproteinases: molecular 
mechanisms and implications for 
extracellular matrix turnover
David J. Wilkinson1, Antoine Desilets  2, Hua Lin1, Sarah Charlton1, Maria del Carmen 
Arques1, Adrian Falconer1, Craig Bullock1,10, Yu-Chen Hsu3, Kristian Birchall4, Alastair 
Hawkins5, Paul Thompson5, William R. Ferrell6, John Lockhart7, Robin Plevin8, Yadan Zhang9, 
Emma Blain9, Shu-Wha Lin3, Richard Leduc2, Jennifer M. Milner1 & Andrew D. Rowan1
Increasing evidence implicates serine proteinases in the proteolytic cascades leading to the pathological 
destruction of extracellular matrices such as cartilage in osteoarthritis (OA). We have previously 
demonstrated that the type II transmembrane serine proteinase (TTSP) matriptase acts as a novel 
initiator of cartilage destruction via the induction and activation of matrix metalloproteinases (MMPs). 
Hepsin is another TTSP expressed in OA cartilage such that we hypothesized this proteinase may 
also contribute to matrix turnover. Herein, we demonstrate that addition of hepsin to OA cartilage 
in explant culture induced significant collagen and aggrecan release and activated proMMP-1 and 
proMMP-3. Furthermore, hepsin directly cleaved the aggrecan core protein at a novel cleavage site 
within the interglobular domain. Hepsin expression correlated with synovitis as well as tumour necrosis 
factor α expression, and was induced in cartilage by a pro-inflammatory stimulus. However, a major 
difference compared to matriptase was that hepsin demonstrated markedly reduced capacity to 
activate proteinase-activated receptor-2. Overall, our data suggest that hepsin, like matriptase, induces 
potent destruction of the extracellular matrix whilst displaying distinct efficiencies for the cleavage of 
specific substrates.
Aberrant proteolysis is a characteristic of pathological tissue remodelling events including osteoarthritis (OA), 
the most common of arthritic diseases. OA is a progressively degenerative disease causing severe pain, disability 
and morbidity. A key characteristic of OA is the breakdown of the cartilage extracellular matrix (ECM), a tissue 
that provides smooth surfaces to allow joint articulation. The chondrocyte is the only cell-type responsible for 
ECM homeostasis as well as the production of proteinases involved in both health as well as disease. Aggrecan 
provides water retention and compressive strength via its hydrophilic properties whilst type II collagen provides 
structural integrity. A subset of the matrix metalloproteinases (MMPs), the collagenases (predominantly MMP-1 
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and MMP-13), specifically degrade native type II collagen1 which is considered an irreversible step in disease2. 
Despite this understanding, MMP inhibition has not proven therapeutically beneficial to prevent cartilage matrix 
destruction, due to a lack of inhibitor specificity and a range of off-target effects1.
ECM breakdown often occurs in the pericellular space such as for the chondrocyte in OA cartilage3, making 
membrane-associated proteinases ideal candidates for an initiating role in tissue turnover. Serine proteinases are 
also key enzymes that contribute to the proteolytic destruction of the cartilage ECM by activating latent proM-
MPs which is a key rate-limiting step (see4 and references therein). We have previously shown that the type II 
transmembrane serine proteinase (TTSP) matriptase is expressed in OA cartilage, and can induce and activate 
proMMP-1 and -35. The destruction of cartilage collagen and aggrecan by matriptase is dependent upon metallo-
proteinase activities and the activation of proteinase-activated receptor-2 (PAR2)5,6. We have previously reported 
roles for PAR2 in inflammatory joint disease7 and OA8,9 and shown PAR2 to be important in the production of 
pro-inflammatory mediators known to drive ECM breakdown such as interleukin-(IL-)1 and tumour necrosis 
factor α (TNFα)10, two cytokines which also upregulate PAR2 expression in cartilage11.
In general, TTSPs have diverse substrate specificities12 although matriptase exhibits many similarities to the 
related TTSP, hepsin. Their overlapping substrate repertoires have been widely reported13–16, with hepsin being 
most highly expressed in liver but also in many other adult tissues17. Like matriptase, hepsin is implicated in a 
number of diseases associated with pathological ECM remodeling, including cancer (reviewed in16,18). Since we 
have also detected hepsin expression in human OA cartilage5, in this study we assessed the impact hepsin activity 
has on ECM destruction using cartilage and OA as a disease model of ECM turnover.
Results
Hepsin induces ex vivo ECM degradation. To test whether hepsin was capable of inducing cartilage 
matrix destruction, recombinant enzyme was incubated with human OA cartilage explant cultures. Hepsin repro-
ducibly induced collagen release from this tissue (Fig. 1A) although this was consistently significantly lower than 
that induced by equimolar amounts of matriptase. Hepsin also induced potent aggrecan degradation but the 
levels of release, compared to matriptase, demonstrated variability between patient samples. As seen previously 
for matriptase5,6, inclusion of the broad-spectrum metalloproteinase inhibitor, GM6001, reproducibly blocked the 
observed hepsin-induced collagen release (Fig. 1B).
Hepsin is a proMMP activator. To assess whether hepsin can activate proMMPs we used cytokine-stimulated 
bovine cartilage explant cultures. In this ex vivo model of cartilage breakdown, addition of proMMP activators 
induces early collagen release5,19. As seen previously, low levels of collagen release were observed at day 7 follow-
ing stimulation with IL-1+OSM5. The addition of hepsin led to a significant increase in collagenolysis which was 
observed at both day 7 and 10 of culture (Fig. 2A, left panel). These data correlated with the levels of active col-
lagenase detected in the media of these cultures which were similar for both hepsin- and matriptase-treated car-
tilages (Fig. 2A, right panel). Hepsin processed proMMP-1 and -3 into proteins corresponding to the molecular 
masses of the mature enzymes (approximately 43 kDa and 46 kDa, respectively; Fig. 2B, left panel), whilst MMP 
activity assays confirmed this processing generated active MMP-1 and MMP-3 (Fig. 2B, right panel). Although 
gelatin zymography indicated proMMP-9 activation following hepsin addition (Fig. 2C), this was most probably 
due to proMMP-3 activation since MMP activity assays failed to demonstrate hepsin-mediated activation of 
proMMP-9 as well as proMMP-8 and -13 (Supplementary Figure 1).
Hepsin is an aggrecan-degrading enzyme. The variable level of aggrecan release induced by hepsin 
(Fig. 1A) led us to assess whether hepsin was capable of direct aggrecan cleavage. Interestingly, hepsin caused 
proteolysis of the aggrecan core protein, as demonstrated by anti-G1 immunoblotting (Fig. 3A, left panel). To 
determine whether hepsin cleaved within the pathologically-relevant aggrecan interglobular domain (IGD), 
incubation with recombinant G1-IGD-G2 (corresponding to amino acids Val20-Gly675 of the aggrecan core pro-
tein) confirmed cleavage within this region (Fig. 3A, right panel) at sites distinct from known metalloproteinase 
cleavage sites (Fig. 3B, left panel). Matriptase also processed this protein, albeit with markedly weaker efficiency. 
N-terminal sequencing of the hepsin-mediated cleavage product (Fig. 3B, right panel) indicated a novel cleavage 
site at Arg375↓Gly376 in close proximity to the known aggrecanase cleavage site (Fig. 3C).
Hepsin expression correlates with synovial inflammation. Many proteinase genes are induced by 
pro-inflammatory mediators, including various cytokine combinations such as IL-1+OSM, in chondrocytes 
and many other cell-types20,21. In this study, we found this cytokine combination also markedly induced hepsin 
expression (Fig. 4A) in cartilage but, interestingly, not matriptase (Supplementary Figure 2). Since inflammation 
is recognized to be a contributing factor in OA, especially TNFα (reviewed in22), we assessed hepsin expression in 
OA synovia and found it to be significantly elevated compared to normal (neck of femur; NOF) synovial tissues 
(Fig. 4B). Notably, there appeared to be two distinct groups in the OA samples: one with very little hepsin expres-
sion as per the normal group, whilst the second had markedly higher expression. Interestingly, overall hepsin 
expression correlated with TNFα expression levels (r = 0.57, p = 0.0034; Supplementary Figure 3). Furthermore, 
immunohistochemistry confirmed the presence of hepsin in OA synovial samples, which correlated with histo-
logical grade of synovitis (Fig. 4C).
Hepsin is a weak PAR2 activator. Since we have previously demonstrated that matriptase directly 
induced MMP expression from cartilage via PAR2 activation5, we investigated the ability of hepsin to activate 
PAR2. Following topical administration of hepsin to murine joints, as reported previously for matriptase5, 
hepsin induced a rapid and reproducible increase in synovial perfusion in wild type PAR2+/+ mice compared 
to PAR2−/− mice (Fig. 5A). However, although the perfusion assay confirmed hepsin can activate PAR2, this 
assay requires non-physiological amounts of enzyme. Therefore, we next quantified receptor activation using 
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SW1353 chondrocytes transfected to constitutively express PAR2. Addition of hepsin to these cells reproduc-
ibly induced the expression of the PAR2-dependent gene IL8; however, an equimolar amount of matriptase 
stimulated significantly more IL8 expression (approx. 6-7 times at 50–100 nM) in the PAR2-expressing cells 
(Fig. 5B). Non-transfected SW1353 cells failed to respond (Supplementary Figure 4). To assess PAR2 activation 
kinetics, a quenched fluorescent peptide mimicking the PAR2 activation sequence confirmed hepsin cleaved 
with significantly reduced catalytic efficiency compared to matriptase (Fig. 5C, left panel) albeit with normal 
Michaelis-Menten kinetics (Fig. 5C, right panel). Finally, we assessed whether subsite specificity and structural 
differences within the active site architecture of matriptase and hepsin could explain the significantly differ-
ent levels of PAR2 activation displayed by these proteinases. Substrate specificity comparisons23 highlighted a 
marked preference of matriptase for the amino acids in the P2 and P2′ positions of the PAR2 activation sequence 
(SKGR↓SLIG). To further explore these observations, we conducted molecular docking of the SKGRSL sequence 
in the active sites of both matriptase and hepsin which indicated that the bulky hydrophobic P2′ Leu sidechain is 
Figure 1. Hepsin induces cartilage degradation in OA cartilage explant cultures. (A) Hepsin or matriptase 
(100 nM) was added to human OA knee cartilage in explant culture. Cartilage from donor #1 (85 y, M) and #2 
(77 y, F) were incubated for 3 days whilst donor #3 (66 y, F) was incubated for 7 days. (B) Hepsin or matriptase 
were added to human OA cartilage in the presence or absence of the metalloproteinase inhibitor GM6001 
(10 µM). Collagen and aggrecan release were measured by hydroxyproline and DMMB assays, respectively. 
Statistical analyses were performed using one-way ANOVA with Bonferroni post-hoc test where: *p < 0.05, 
***p < 0.001 versus hepsin; and ††p < 0.01, †††p < 0.001 versus control; ###p < 0.001 versus hepsin or matriptase 
only. Data are plotted as mean ± SD and representative of at least 3 independent experiments (n = 4).
www.nature.com/scientificreports/
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Figure 2. Hepsin is an activator of proMMP-1 and proMMP-3. (A) Bovine nasal cartilage explants were 
stimulated with IL-1 (1 ng/ml) and OSM (10 ng/ml) in the presence and absence of matriptase or hepsin 
(100 nM). Media were removed and the cartilage re-stimulated at day 7. The experiment was terminated as 
described in the experimental procedures, and the percentage collagen release determined by hydroxyproline 
assay. Left panel: Data are presented as day 7 collagen release and total collagen release (day 7 + 10). Right panel: 
Collagenase activity in Day 7 media was monitored by a 3H collagen bioassay. Data are plotted as mean ± SD 
(n = 6) and representative of 3 independent experiments. Statistical significance was measured by one-way 
ANOVA with Bonferroni post-hoc test where ***p < 0.001 vs IL-1+OSM. (B) Recombinant full-length 
proMMP-1 or proMMP-3 were incubated with recombinant hepsin in a 1:5 serine proteinase:MMP molar 
ratio at 37 °C for up to 24 h. Left panel: Products were separated by 10% SDS-PAGE and gels stained with silver. 
Right panel: For activity assays, proMMP-1 or proMMP-3 were incubated with hepsin or matriptase for 4 h at 
37 °C. Enzyme to substrate ratios were 1:5 for proMMP-1 and 1:10 for proMMP-3. MMP activity was assessed 
with the MMP-specific substrate FS-6. ProMMP alone or in the presence of APMA were used as negative and 
positive controls, respectively. Hepsin and matriptase without MMP did not cleave the substrate significantly. 
Hepsin and matriptase were also pre-treated with the irreversible serine proteinase inhibitor di-isopropyl 
fluorophosphate (DFP), to demonstrate the involvement of serine proteinase activity in MMP activation. Data 
are presented as a percentage of APMA-activated proMMP (mean ± SD) following subtraction of the blank 
measurement. Statistical significance was measured by a one-way ANOVA with Bonferroni post-hoc test where 
***p < 0.001 compared to proMMP alone. (C) Day 7 culture media from stimulated bovine cartilage in A 
were subjected to gelatin zymography. Where gel images have been cropped for clarity, full length images are 
presented in supplementary information.
www.nature.com/scientificreports/
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Figure 3. Hepsin degrades aggrecan. (A) Hepsin cleaves within the interglobular domain of aggrecan. Left 
panel: Deglycosylated bovine aggrecan (400 nM) was incubated with hepsin, matriptase or trypsin (all 10 nM) 
for 16 hours at 37 °C. Incubation products were separated on a 7.5% SDS-PAGE gel and western blotted using 
an antibody recognising the aggrecan G1 domain. Results are representative of 3 independent experiments. 
Right panel: Hepsin generates a novel cleavage within the aggrecan IGD. Recombinant human G1-IGD-G2 
was incubated with matriptase or hepsin in a 1:20 enzyme to substrate ratio (156 nM G1-IGD-G2 and 7.8 nM 
proteinase) for 16 h at 37 °C then resolved by SDS-PAGE and stained with silver. (B) Left panel: In a similar 
experiment, products were western blotted using BC-3 and BC-14 neoepitope antibodies. Incubation of G1-
IGD-G2 with ADAMTS-5 (1.6 μg/ml) and MMP-13 (6 μg/ml) acted as positive controls for aggrecanase and 
MMP cleavage, respectively. Right panel: G1-IGD-G2 (156 nM) was incubated with hepsin (7.8 nM) for 8 h at 
37 °C. Products (Ia, Ib, IIa and IIb) were separated by SDS-PAGE and stained with silver, western blotted using 
an anti-G1 aggrecan antibody or blotted onto PVDF and stained with Coomassie brilliant blue R250, after 
which the desired band (IIb) was excised and subjected to N-terminal sequencing. Where images have been 
cropped for clarity, full-length gels/blots are presented in supplementary information. The bands on each figure 
are taken from the same gels/blots under the same exposure conditions. (C) N-terminal sequencing identifies 
novel cleavage site. Left panel: Schematic representation of the hepsin-cleaved aggrecan fragments based on 
data from B. The desired product (IIb; red line), corresponding to the new N-terminus following cleavage 
(red dashed box in B), was excised from a Coomassie-stained blot. Right panel: Known MMP and aggrecanase 
cleavage sites within the aggrecan IGD including the novel hepsin cleavage at Arg375↓Ser376 confirmed by 
N-terminal sequencing (highlighted by red arrow).
www.nature.com/scientificreports/
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better accommodated in the deep hydrophobic channel of matriptase compared to the more shallow and polar 
S2′ pocket offered by hepsin. Furthermore, the Gly residue in the P2 position of the PAR2 peptide has better com-
plementarity to the receptor surface in matriptase, engaging in Van der Waals contacts with a Phe residue that 
is absent from the more open S2 pocket of hepsin (Fig. 6). These structural data are consistent with the notion 
that hydrolysis of the PAR2 activation sequence (SKGR↓SLIG) by hepsin is considerably less favourable than that 
provided by matriptase.
Figure 4. Hepsin expression is associated with inflammation. (A) Bovine articular cartilage was excised 
from metacarpophalangeal joints and stimulated with IL-1 (5 ng/ml) and OSM (10 ng/ml) for 4 days. RNA 
was isolated and reverse transcribed prior to real-time PCR. Data were normalized to the level of 18 S rRNA 
and plotted as mean ± SD fold change (n = 4). Significant differences were determined using a t-test where 
***p < 0.001. (B) Gene expression levels in hip synovium from patients with OA (closed circles; n = 12) or 
normal controls (NOF) (open squares; n = 12) of HPN were determined as described in the Experimental 
procedures and normalized to the level of glyceraldehyde 3-phosphate dehydrogenase (GAPDH). HPN 
expression was undetected in 8/12 NOF samples and 2/12 OA samples, and significant differences between the 
normal and OA groups were determined using a two-sided Mann-Whitney U test, where **p < 0.01. (C) Human 
OA synovia samples were fixed, embedded in paraffin, sectioned and stained with haematoxylin and eosin. 
Synovitis was scored blinded by two independent scorers based on levels of inflammation, stromal activation 
and hyperplasia. Summed scores were totaled and described as no synovitis (0–1), slight synovitis (2–3), and 
moderate synovitis (4–6). Representative samples from within this scoring scale are presented where hepsin was 
detected by immunohistochemistry using a rabbit anti-hepsin polyclonal antibody. A control consisting of no 
primary antibody (NPA) was also performed. The scale bars represent 100 µm (except 50 µm for the insets).
www.nature.com/scientificreports/
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Discussion
Despite our understanding of the importance of metalloproteinases in ECM destruction, and the requirement 
for proMMP activation24–26, the interplay between serine and metalloproteinases is still an emerging paradigm4. 
Moreover, human OA cartilage is particularly resistant to resorption in vitro, and we have previously observed 
that although addition of potent cytokine stimuli such as IL-1 + OSM produce high proMMP levels, significant 
collagen release is rarely observed6,20. It is now believed that serine and metalloproteinase cascades are intercon-
nected during cartilage catabolism, and such interplay likely functions in other connective tissue pathologies. The 
identity of specific serine proteinases, however, has remained elusive. Recent genomic and proteomic advances 
helped discover entirely novel families of proteinases, including TTSPs16,18. Of this family, we previously reported 
matriptase expression to be elevated in end-stage OA, identifying it to have a putative role as an initiator of 
cartilage collagen destruction by inducing the expression and, crucially, activation of proMMPs5. Herein, we 
now describe a second TTSP, hepsin, can also activate proMMPs and thus promote ECM turnover. Moreover, as 
shown previously for matriptase which induced early collagen release5, hepsin also increased collagenase activity 
to comparable levels suggesting similar capabilities in activating relevant proMMPs that promote collagenolysis. 
In vitro proMMP activation experiments further confirmed hepsin and matriptase display similar propensities for 
the activation of both proMMP-1 and proMMP-3. Indeed, hepsin activity is important for prostate and ovarian 
cancer cell invasion, a process linked to metalloproteinase activity in many circumstances27–30.
Data from an OA model now indicate that ECM remodeling events are phasic, with significant changes occur-
ring throughout the disease course primarily as a result of changes to the joint microenvironment31; in reality, 
Figure 5. Hepsin is a weak PAR2 activator. (A) To assess the ability of hepsin to activate PAR2 in vivo, hepsin 
(5 µg) was administered topically to an exposed knee joint of both PAR2+/+ (●; n = 3) and PAR2−/− (○; n = 4) 
mice, with synovial perfusion monitored by high resolution Doppler imaging, as described previously5. Data 
are presented as percentage change in perfusion from the baseline mean ± SEM. (B) Hepsin or matriptase 
(10–100 nM) were added to SW1353 cells stably expressing PAR2 for 3 hours. Cells were lysed, mRNA 
reverse transcribed and IL8 expression monitored by real-time PCR. Data were normalized to an 18S rRNA 
housekeeping gene and plotted as fold change compared to unstimulated cells. (C) Matriptase is a more potent 
PAR2 activator. Left panel: Hepsin (1 nM) or matriptase (1 nM) were incubated with 2-Abz-SKGRSLIG-Y(NO2) 
(0–200 μM), fluorescence monitored and linear reaction velocities obtained from progress curves. Velocities 
were plotted against substrate concentration and Michaelis-Menten constants generated by non-linear 
regression. Right panel: Expanded view of the non-linear regression for hepsin confirming normal Michaelis-
Menten kinetics. Curves are representative of 3 independent experiments. Tabulated kinetic constants are also 
shown as mean ± SD across each of 3 independent experiments.
www.nature.com/scientificreports/
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these genotypic/phenotypic fluctuations are likely in many pathological matrix remodelling scenarios. Moreover, 
it is now widely accepted that inflammation (typically cytokine-mediated) is a contributing factor that drives and 
perpetuates ECM turnover in OA32,33 as well as being a prime effector of matrix remodeling in many inflamma-
tory pathologies. Our finding that hepsin is markedly up-regulated in chondrocytes in response to the catabolic 
stimulus IL-1 + OSM20,21 suggests hepsin expression is dynamic and highly regulated. Furthermore, this expres-
sion was consistent with the concomitant up-regulation of MMP substrates such as proMMP-1 and proMMP-3 
to effect ECM turnover21,34.
The importance of proMMP-3 activators in the destruction of ECMs cannot be understated since this protein-
ase is capable of activating many other MMPs including MMP-1335. Although hepsin activation of proMMP-1 
was relatively weak in vitro, proteolytic attack of proMMP-1 by a serine proteinase typically produces a partially 
active MMP which only becomes fully active following further cleavage by active MMP-336,37. It is well estab-
lished, for example, that cartilage ECM destruction involves multiple interdependent proteolytic cascades, the 
corollary of which is that some proteinases must function as upstream initiators. Interestingly, matriptase and 
hepsin undergo auto-activation, a unique phenomenon consistent with TTSPs functioning in this role38 although 
hepsin has also been reported to activate pro-matriptase17. With the initial stages of cartilage destruction localised 
to the pericellular space, somewhat analogously to an ‘invasive front’, membrane-anchored serine proteinases are 
ideally positioned for proMMP activation and the subsequent destruction of the surrounding pericellular matrix. 
To our knowledge, this is the first report demonstrating the ability of hepsin to activate proMMPs, and may have 
significant implications in settings where metalloproteinase-dependent matrix turnover is prevalent.
An intriguing finding was that the aggrecan IGD is a substrate for hepsin, cleavage occurring very close to the 
reported aggrecanase processing site. Our previously reported P1-P1′ specificity data for hepsin39 are consistent 
with the observed cleavage at Arg375↓Gly376. Although it is likely that the majority of catabolic events in cartilage 
are effected by metalloproteinases, our data suggest hepsin has the potential to generate an aggrecan peptide 
(Phe342-Arg375) very similar to the bioactive Phe342-Glu373 peptide (generated by combined MMP and aggrecanase 
activities) known to contribute to cartilage breakdown40 in the absence of aggrecanase activity. Thus, hepsin 
acting as a proMMP activator may further exacerbate ECM turnover in aggrecan-rich ECMs. It has also been 
shown to cleave the structurally ubiquitous basement membrane component laminin-332, as indeed have several 
MMPs, which helps maintain epithelial-mesenchymal cohesion in tissues exposed to external forces; laminin-332 
cleavage may generate pro-migratory signals to cells (see41 and references therein). Combined with its ability to 
activate pro-hepatocyte growth factor42, hepsin is therefore capable of promoting invasion and metastasis.
Since we have previously demonstrated that matriptase-induced breakdown of OA cartilage is 
PAR2-dependent5,6 and that PAR2 antagonism is protective8, we investigated the propensity for hepsin to acti-
vate PAR2 in comparison to matriptase. We demonstrated that hepsin cleaved and activated PAR2 in vivo, albeit 
in a somewhat non-physiological setting. Kinetic assessment of PAR2 cleavage however highlighted a signif-
icantly reduced capability of hepsin to cleave PAR2 compared to matriptase. Consistent with these findings, 
hepsin-deficient mice subjected to destabilisation of the medial meniscus (DMM) surgery to induce OA were not 
Figure 6. Structural modelling of hepsin explains poor PAR2 activation. The PAR2 cleavage sequence peptide 
(SKGR↓SL) is docked into matriptase and hepsin and displayed side-by-side for comparison. The peptide is 
shown in ball and stick representation, receptor surfaces are coloured by electrostatic potential, H-bonding 
interactions are indicated with pink dashes and sub-pockets labelled. The binding sites are largely similar 
and the peptide binds in the same way. The most significant difference is in the S2′ pocket where the deep 
hydrophobic channel in matriptase better accommodates the Leu sidechain of the peptide compared to the 
polar shallow pocket in hepsin. The S2 pocket is also a significant point of difference with the peptide Gly 
residue engaging in Van der Waals contacts with the Phe sidechain in matriptase, which is absent in the more 
open pocket of hepsin (insets show a close up of the S2 pocket from a different angle with the peptide in a 
spacefill format, including hydrogen atoms).
www.nature.com/scientificreports/
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protected from cartilage damage (Supplementary Figure 5). We have previously demonstrated the importance 
of the matriptase/PAR2 axis in the DMM model6,8,9 whereby PAR2 activation is a significant contributor to the 
observed cartilage damage. We hypothesise little or no activation of PAR2 by hepsin in cartilage explains the lack 
of protection in the DMM-treated hepsin-deficient mice and accounts for the lower levels of hepsin-induced col-
lagen release from human OA cartilage explants compared to matriptase, whilst the similar efficiencies of MMP 
activation for both TTSPs further support this assumption. Indeed, weak activation of PAR2 by hepsin (relative 
to matriptase) has been reported previously in a study which indicated that hepsin-mediated PAR2 activation was 
primarily matriptase-dependent due to its activation by hepsin17.
Canonical PAR2 activation occurs at..SKGR↓SLIG.. and experimental substrate preference data23,39 indicate 
that matriptase prefers small residues at P2 (Gly/Ala) whilst hepsin is more tolerant and generally prefers larger 
side chains (Ala/Gln/Pro/Leu). Thus, although Gly at this position in the PAR2 sequence is accepted by hepsin, it 
is a much more preferred requirement in matriptase. Moreover, structural modelling provides some rationale for 
the observed substrate difference; Asn254 in the S2 pocket of hepsin provides much more space but less favoura-
ble surface complementarity than the corresponding Phe708 in matriptase. The other key difference in substrate 
preference is at the P2′ position where the Leu residue in the PAR2 sequence is well tolerated in matriptase but 
much less so in hepsin.
As hepsin gene expression is responsive to pro-inflammatory cytokines, and correlates with synovitis from 
human OA patients, we conclude that hepsin may have a role in cartilage destruction that has a more inflam-
matory phenotype. Indeed, increasing evidence supports a role for inflammation in OA progression amongst a 
subset of patients33 which mirrored our findings, whilst the DMM model is known to have little inflammatory 
involvement43. Thus, herein we demonstrate that hepsin is a proteinase that directly and indirectly promotes 
pathological ECM alterations (see Fig. 7). Indeed, we propose that its ability to function as an activator of proM-
MPs and other proteinase zymogens may have implications in not only arthritis but many other matrix remode-
ling scenarios such as cancer metastasis and invasion.
Experimental procedures
Reagents and antibodies. All chemicals of the highest purity available were obtained from Sigma 
Chemical Co (Poole, UK) unless otherwise stated. All cytokines and proteins used were recombinant human 
unless stated otherwise. IL-1α was a generous gift from Dr Keith Ray (GlaxoSmithKline, Stevenage, UK). 
Oncostatin M (OSM), proMMP-1, proMMP-13, matriptase (aa596-895) and hepsin (aa45-417) were produced 
in-house (see6,12 and references therein). Purified serine proteinases were active site titrated with the burst titrant 
4-methylumbelliferyl-p-guanidinobenzoate. ProMMP-3 and proMMP-8 were purchased from R&D Systems 
(Abingdon, UK). GM6001 was purchased from Calbiochem (Nottingham, UK). The anti-G1 antibody was kindly 
Figure 7. Schematic of the direct and indirect contributions of hepsin to alter ECM integrity. Firstly, hepsin 
activity is known to modulate cell motility via laminin 33252. Hepsin activates the uPA/plasminogen/plasmin 
cascade and also processes latent hepatocyte growth factor (HGF) leading to HGF/cMet signaling; together, 
these promote metastasis and altered epithelial cohesion30,53. Moreover, hepsin can activate pro-matriptase17 
which leads to PAR2 activation and subsequent expression of proMMP-3 and proMMP-15 as well as 
inflammatory mediators including IL-854 leading to chemotaxis of inflammatory cells such as neutrophils and 
mast cells. Plasmin55, as well as hepsin, generate active MMP-3 which is a prime activator of many proMMPs 
including proMMP-1 and proMMP-13, key collagen-degrading proteinases. Inflammation induces the 
expression of prohepsin which auto-activates17,38 and can directly activate proMMP-1 as well as cleave within 
the aggrecan IGD to promote both aggrecanolysis and collagenolysis to further impair the structural integrity of 
tissues.
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provided by Dr John Mort (McGill University, Canada). BC-3 and BC-14 aggrecan antibodies were provided by 
Prof. Bruce Caterson (Cardiff University, UK). Ab25 was kindly provided by Dr Daniel Kirchhofer (Genentech, 
CA, USA) and produced as described44. The MMP substrate, fluorescence substrate-6 (FS-6) was purchased from 
Merck Millipore (Watford, UK), whilst the quenched fluorescent peptide 2-Abz-SKGRSLIG-Y(NO2) was synthe-
sized by GL Biochem (Shanghai, China).
Cartilage explant culture. Explants were taken from macroscopically normal areas of cartilage from OA 
patients, undergoing total knee replacement at the Freeman Hospital, Newcastle. All tissue was obtained following 
informed consent from patients, and processing and handling carried out in accordance with University guide-
lines with appropriate ethical approval from NHS Health Authority NRES Committee North East – Newcastle 
and North Tyneside 1 (REC14/NE/1212). Cartilage was prepared and cultured as described previously6, and 
stimulated with recombinant TTSP for either 3 or 7 days. For bovine cartilage explants, nasal septum (obtained 
from a local abattoir) was prepared as previously described20. Two discs were plated in each well of a 48-well plate 
and incubated in serum-free medium overnight. Cartilage was stimulated with IL-1 + OSM (1 ng/ml and 10 ng/
ml, respectively) in the presence or absence of matriptase or hepsin (100 nM). Cartilage was re-stimulated at day 
7 and the experiment terminated following complete resorption of ≥1 of the wells (typically day 10–12). Media 
were removed and stored at −20 °C prior to analysis. The remaining cartilage was digested with papain20. To 
analyse cartilage destruction, hydroxyproline levels were used as an estimate for collagen release into conditioned 
medium, whilst aggrecan release was measured by assessing levels of glycosaminoglycan (GAG) by dimethyl 
methylene blue (DMMB) assay (see20 and the references therein). Collagenolytic activity present in culture media 
from cartilage explants was determined using a diffuse fibril assay with 3H acetylated collagen45. Gelatin zymog-
raphy was performed as previously described25. For cytokine experiments, bovine articular explants were stim-
ulated for a total of 96 hours with IL-1α (5 ng/ml) and oncostatin-M (10 ng/ml). Explants were snap frozen and 
homogenised in TRIzol® (Invitrogen, Paisley, UK) in liquid nitrogen using a dismembrator (Sartorious, Epsom, 
UK), RNA extracted and complementary DNA synthesised using Superscript III reverse transcriptase according 
to the manufacturer’s instructions (Invitrogen). Real-time PCR was performed using a MxPro3000 QPCR system 
(Agilent Technologies, Stockport, UK) using ReadyMix™ Taq PCR reaction mix in conjunction with a Taqman® 
gene expression assay (Hpn: Bt03260765_m1; ThermoFisher Scientific (Loughborough, UK)). 18 S was used as a 
reference gene as previously described46.
ProMMP activation and SDS-PAGE. Recombinant hepsin and matriptase were incubated with 
proMMP-1, proMMP-8, proMMP-9 and proMMP-13 at a 1:5 enzyme to MMP ratio whilst proMMP-3 was at 
a 1:10 ratio. Each proMMP was activated with 4-aminophenylmercuric acetate (APMA; 0.67 mM) as a positive 
control24. To demonstrate the requirement for serine proteinase activity, TTSPs were also pre-treated with the 
irreversible serine proteinase inhibitor di-isopropyl fluorophosphate (DFP; 2 mM). Each preparation was adjusted 
to a final volume of 20 µl in 100 mM Tris pH 8.0, 150 mM NaCl, 10 mM CaCl2, 0.01% (w/v) Brij 35 and incubated 
for 4 hours at 37 °C. Resultant MMP activity was assessed by the MMP-specific quenched fluorescent peptide, 
FS-6. Briefly, samples were incubated in duplicate at 37 °C in 100 mM Tris pH 7.5, 100 mM NaCl, 10 mM CaCl2, 
0.01% (w/v) Brij 35, 0.1% (v/v) polyethylene glycol 6000 prior to FS-6 addition (50 µM final concentration) in 
100 µl final volume. The reaction was allowed to proceed at 37 °C until approximately 10% substrate hydrolysis 
was reached, before being stopped by the addition of 50 µl 2 M sodium acetate. Fluorescence was monitored at 
325 nm λexcitation and 405 nm λemission in a Perkin Elmer LS50B plate reader. For time-course experiments, hepsin 
was incubated with proMMP-1 and proMMP-3 in a 1:5 hepsin:proMMP ratio, and aliquots taken at various time 
points from 30 minutes to 24 hours.
Proteins were resolved by sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) using a 
Mini-Protean tetra-cell apparatus (BioRad, Herts, UK) with separate resolving (10% (w/v) acrylamide/bisacryla-
mide (37.5:1), 375 mM Tris HCl, pH 8.8, and 0.1% (w/v) SDS) and stacking (4.5% (w/v) acrylamide/bisacryla-
mide (37.5:1), 125 mM Tris HCl, pH 6.8, 0.1% (w/v) SDS) gels. Samples, including molecular mass markers (5 
μl: PageRuler Prestained, Thermofisher) were reduced and boiled in 5x SDS-PAGE loading buffer (625 mM Tris 
HCl pH 6.8, 10% (w/v) SDS, 40% (v/v) glycerol, 0.5% (w/v) bromophenol blue, 5% (v/v) β-mercaptoethanol) for 
5 minutes prior to electrophoresis in 1 mm thick gels using 25 mM Tris HCl, 20 mM glycine, 1% (w/v) SDS run-
ning buffer. Following separation, gels were stained with silver according to the manufacturer’s instructions (Plus 
One silver staining kit, GE healthcare, Buckinghamshire, UK).
Aggrecan digestion. Deglycosylated aggrecan was extracted from bovine nasal cartilage as described previ-
ously47. Recombinant hepsin or matriptase (both 10 nM) were incubated with 400 nM aggrecan in 100 μl final vol-
ume made up with 100 mM Tris pH 8.5, 150 mM NaCl, 0.01% (w/v) Brij 35) and incubated for 16 hours. Products 
were reduced, boiled, separated by SDS-PAGE (as described above), semi-dry blotted onto PVDF and western 
blotting carried out using an anti-G1 antibody. For proteolysis of recombinant G1-IGD-G2 (R&D Systems), pro-
teinases were incubated at a 1:20 enzyme to substrate ratio (7.8 nM and 156 nM, respectively) in a final volume 
of 120 μl. Cleavage products were separated by SDS-PAGE and first stained with silver or immunoblotted using 
aggrecan neo-epitope antibodies recognizing MMP- or aggrecanase-specific cleavages. In subsequent experi-
ments, digestion products were transferred to PVDF and either stained for 2 minutes with Coomassie Brilliant 
Blue R250, or immunoblotted with an anti-G1 antibody to assist identification of the specific band of interest 
which was excised and N-terminal sequenced (Cambridge Peptides, Birmingham, UK).
Synovial Tissue and Immunohistochemistry. Human synovia were generously provided by Prof Ian 
Clark (University of East Anglia, Norwich, UK) from patients undergoing total hip replacement surgery at the 
Norwich and Norfolk Hospital, Norwich, UK for OA (6 M/6 F; mean age = 74.3 yrs (±3.6 SD), range 68–78 yrs) or 
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NOF fracture (2 M/10 F; mean age = 76 yrs (±10 SD), range 52–89 yrs). Human knee synovia were obtained from 
OA patients undergoing total knee replacement surgery (3 M/8 F; mean age = 65.6 yrs (±8.4 SD), range 54–86 
yrs), at the Freeman Hospital, Newcastle, UK. All tissue was obtained following informed consent from patients, 
and processing carried out in accordance with University guidelines and with ethical approval from either 
Norfolk Research Ethics Committee (REC05/Q010/196) or NHS Health Authority NRES Committee North 
East – Newcastle and North Tyneside 1 (REC14/NE/1212). RNA was isolated from hip synovia and subjected to 
TaqMan low density array PCR as previously described5,48. Knee synovial tissue was fixed overnight in 10% for-
malin and paraffin embedded as described6. Sections were generated at 4 μm intervals and stained with haemo-
toxylin and eosin as described previously19. Synovitis was scored according to a previously described system49. For 
immunohistochemistry, sections were de-waxed in xylene followed by decreasing alcohol gradients and antigen 
retrieval performed by immersion in hot 10 mM sodium citrate, pH 6.0, for 6 minutes. Endogenous peroxidase 
activity was quenched in 0.3% (v/v) H2O2 for 30 minutes. A biotin block was performed according to the manu-
facturer’s instructions (Vector Laboratories, CA, USA), followed by blocking in 5% horse serum. Hepsin antibody 
at 1:100 dilution (Cayman Chemicals, Michigan, USA) was applied for 30 minutes. After washing, detection was 
performed using an ABC peroxidase staining kit (Thermofisher Scientific, Loughborough, UK) according to the 
manufacturer’s instructions, followed by incubation with 3, 3′-diaminobenzidine tetra-hydrochloride (DAKO, 
Ely, UK) for 5 minutes. Sections were washed in tap water, counterstained with Mayer’s haemotoxylin and slides 
mounted. Images were taken using a Leica Biosystems DM4000B light microscope.
PAR2 assays. All mice were C57BL/6 J background, and housed in standard cages. All procedures 
were approved and conducted in accordance with UK Home Office legislation (project licence number 
70/8790) and institutional regulations. Food and water was available ad libitum and all animals were kept in 
a thermoneutral environment. In vivo PAR2 activation was assessed by consecutive laser Doppler imag-
ing (Moor Instruments, Axminster, UK) of synovial perfusion following administration of hepsin (5 µg) 
to PAR2+/+ and PAR2−/− mice, as described previously5. For cell experiments, full-length PAR2 was 
amplified from a commercially available shuttle vector (R&D Systems, Abingdon, UK) and cloned into a 
pcDNA3.1 vector using an Infusion-HD kit (Clontech, CA, USA) according to the manufacturer’s protocol. 
5′-TACCGAGCTCGGATCGCCACCATGGACTACAAGGATGACGATGACAAGCGAAGTCCTAGTGCT-3′ 
and 5′-AAACGGGCCCTCTAGTTAATAGGAGGTCTTAACAG-3′ were used as forward and reverse primers, 
respectively, which provided an N-terminal FLAG tag and kozak sequence. SW1353 chondrosarcoma cells were 
cultured as described previously50. For transfection, 2.75 µg plasmid DNA with 8.25 µl Fugene-HD transfection 
reagent (Promega, Southampton, UK) were added to cells for 48 hours in antibiotic-free medium followed by 
selection in medium containing G418 disulphate (neomycin analogue, 400 µg/ml). Cells were incubated with 
matriptase or hepsin (0–100 nM) for 3 hours. RNA was stabilised in Cells-to-cDNA lysis buffer and converted to 
cDNA by Moloney-Murine Leukemia Virus reverse transcriptase as directed (Invitrogen). IL-8 (CXCL8) expres-
sion was monitored by TaqMan real-time PCR (forward primer: 5′-AGACAGCAGAGCACACAAGC-3′; reverse 
primer: 5′AGGAAGGCTGCCGAGAG-3′; Probe: #72 from Universal Probe Library (Roche, Welwyn Garden 
City, UK), and normalised to 18 S ribosomal RNA levels (primers and probe as described in51). The kinetics of 
PAR2 cleavage by hepsin or matriptase (both 1 nM) were assessed in pre-warmed 100 mM Tris pH 7.5, 150 mM 
NaCl, 500 µg/ml bovine serum albumin, 0.01% (w/v) Brij 35 before addition of 2-Abz-SKGRSLIG-Y(NO2) at a 
range of concentrations (up to 200 µM). Progress curves were monitored over 30 minutes at 37 °C, and slopes 
from the linear portions of each curve plotted against substrate concentration and kinetic constants generated by 
non-linear regression using GraphPad Prism 7.0 software.
Molecular Modelling. All operations were performed within the Schrödinger Molecular Modelling Suite 
version 2017-1 (NY, USA). Crystal structures of matriptase and hepsin were downloaded from the Protein Data 
Bank (3PF8 and 1ZG8, respectively) and aligned using the backbone atoms of chain A. The amino acid sequence 
RCTKSI of the bound peptide (chain I) was extracted from 3PF8 and mutated to the PAR2 cleavage sequence 
SKGRSL. The termini of the resulting PAR2 peptide were amide capped and restrained minimization performed 
using Impact. Glide SP was used to obtain a rough positioning of the peptide in the binding sites of matriptase 
and hepsin (flexible peptide, rigid receptor), followed by refinement using Prime MM-GBSA, allowing simulta-
neous sampling of peptide and receptor, with full flexibility for residues within 6 Å of the peptide.
Statistical analysis. Statistical differences between sample groups were assessed using ANOVA with 
a post-hoc Bonferroni’s multiple comparison test. For comparisons between only two samples, a two-tailed 
Student’s t-test was performed. A Pearson correlation co-efficient calculation was performed for synovial gene 
expression data. All statistical analyses were performed using Graphpad Prism 7.0 software where ***p < 0.001; 
**p < 0.01; *p < 0.05.
Equipment and Settings. All gel and blot images were taken using Syngene using GeneSnap software. 
Western blots were detected after 5 minutes in enhanced chemiluminescent (ECL) substrate. Images were cap-
tured under ‘no light’ conditions with 5 × 30 seconds exposure time. Upper white images were taken to determine 
the position of the ladder, and composite images generated using GeneSnap. Images of silver stain gels were taken 
using the ‘transilluminator’ setting, using a visible light converter screen to produce an evenly illuminated area of 
white light. Any changes to brightness or contrast were applied uniformly across the whole gel or blot.
Data Availability. The datasets generated/analysed during the current study are available from the corre-
sponding author on reasonable request.
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